Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications

Cancer Gene Ther. 2022 Oct;29(10):1307-1320. doi: 10.1038/s41417-022-00434-9. Epub 2022 Feb 18.

Abstract

FUS1/TUSC2 (FUSion1/TUmor Suppressor Candidate 2) is a tumor suppressor gene (TSG) originally described as a member of the TSG cluster from human 3p21.3 chromosomal region frequently deleted in lung cancer. Its role as a TSG in lung, breast, bone, and other cancers was demonstrated by several groups, but molecular mechanisms of its activities are starting to unveil lately. They suggest that Fus1-dependent mechanisms are relevant in etiologies of diseases beyond cancer, such as chronic inflammation, bacterial and viral infections, premature aging, and geriatric diseases. Here, we revisit the discovery of FUS1 gene in the context of tumor initiation and progression, and review 20 years of research into FUS1 functions and its molecular, structural, and biological aspects that have led to its use in clinical trials and gene therapy. We present a data-driven view on how interactions of Fus1 with the mitochondrial Ca2+ (mitoCa2+) transport machinery maintain cellular Ca2+ homeostasis and control cell apoptosis and senescence. This Fus1-mediated cellular homeostasis is at the crux of tumor suppressor, anti-inflammatory and anti-aging activities.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Aging
  • Anti-Inflammatory Agents
  • Genes, Tumor Suppressor
  • Homeostasis
  • Humans
  • Lung Neoplasms* / genetics
  • Tumor Suppressor Proteins* / genetics

Substances

  • Anti-Inflammatory Agents
  • Tumor Suppressor Proteins
  • TUSC2 protein, human